Zelluna held its Third Quarter 2026 Results Webcast Including ZIMA-101 Clinical Progress Update
Zelluna held a WEBCAST and published its financial results for the third quarter of 2026 on Thursday, 5 November 2026 at 09:00 CET.
The quarterly report and presentation materials are available in Financial Reports
Poster presented at ESMO 2026
Cell Therapies Can “Cure” Cancers
Cell therapies have delivered “cures” in certain late-stage cancer patients with multiple approved treatments mainly for liquid cancers. Several cell therapy products have been approved by regulatory authorities with data from fewer than 100 patients.
Solid Cancers remain a major challenge
Whilst there has been progress, successes in liquid cancers have not translated into solid cancers, which represent by far the largest cancer burden and remain an unsolved challenge.
Zelluna targets Solid Cancers
Zelluna is developing a unique and proprietary TCR-NK cell therapy platform.
TCR-NK therapies are designed to overcome the current challenges of treating solid cancers and can potentially be used to treat a range of solid cancers with unmet medical need in high value markets.
Saving lives through innovative targeted cancer therapies
Zelluna is a clinical stage company with a mission to eliminate solid cancers by unleashing the most powerful elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies. The team comprises experienced biotech entrepreneurs who have taken immuno-oncology projects from inception through to the clinic, supported by a highly experienced international board.
